+ Watch ONCY
on My Watchlist
A development stage company focuses on the discovery and development of oncolytic viruses for the treatment of cancers.
Oncolytics is a speculative play, no doubt. No completed Ph3 yet. It has one drug. A small cap with little cash. So why buy. Simple. Risk reward. ONCY is trying to cure cancer, as are many. What differentiates it, is it's one drug's mechanism of action, if proven successful, will work against many common cancer indications. That gives it a big revenue potential relative to current market cap. The side effect profile is minimal and generally well understood. The virus itself is well known scientifically and generally benign in humans. The drug (a virus) has proven in early trials to be capable of dramatic outcomes. Since it works synergistically with chemotherapy, trials are easy to design and set up. Give standard of care and standard of care plus Reosylin. If it is proven to work in one indication, stock price will appreciate significantly from current levels. Given that there are many indications entering trials recently, with gov't and health institute support, those in the research community must see some possibility of success. So if you are willing to invest in what are very risky biotech companies, this company is not a bad choice, as they are focussed on one thing, Reosylin, that if successful, could used in conjunction with standard of care across many different cancers.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions